Skip to main content
. 2022 Apr;17(4):568–569. doi: 10.2215/CJN.01840222

Table 3.

Study N Methods Standard Definition of Bloodstream Infection Used Definition of Bloodstream Infection Antimicrobial Locking Solution Control Outcome Rate/1000 Catheter-Days P Value Concerns
Solomon et al. (74) 174 Prospective, cohort study compared with historical controls No A single positive blood culture Taurolidine 1.35%/citrate 4%/heparin 500 U/ml a) Heparin 5000 U/ml a1) Bloodstream infection a1) 1.33 versus 3.25 a1) 0.001 Cost
b) Taurolidine 1.35%/Citrate 4%
a2) First use of thrombolytic a2) RR 1.4 (0.5–3.9) a2) 0.5
b1) Blood stream infection b1) 1.33 versus 1.22 b1) 0.001
b2) First use of thrombolytic b2) RR0.2 (0.06 to 0.5) b2) 0.001
Winnicki et al. (75) 106 Multicenter, randomized, controlled trial No A positive bacterial blood culture drawn from the dialysis catheter in a symptomatic patient with fever or chills associated with dialysis and no apparent other source of infection Taurolidine 1.35%/citrate 4%/heparin 500 U/ml twice a wk with taurolidine 1.35%/citrate 4%/urokinase 25,000 U once a wk Citrate 4% a) Bloodstream infection a) 0.67 versus 2.7 0.003 Cost
b) Catheter dysfunction b) 18.7 versus 44.3 0.001
Al-Ali et al. (76) 164 Multicenter, single- blinded, randomized, controlled trial No Same organism obtained from blood aspirated through the catheter hub and from blood sample obtained from peripheral vein with no other identifiable cause of infection Taurolidine 1.35%/citrate 4%/heparin 500 U/ml twice a wk with taurolidine 1.35%/citrate 4%/urokinase 25,000 U once a wk Taurolidine 1.35%/citrate 4%/heparin 500 U/ml three times a wk a) Catheter removal for bloodstream infection a) 0 versus 3 0.08 Cost
b) Catheter removal for dysfunction b) 1 versus 4 0.17
c) Need for tissue plasminogen activator use c) 5 versus 12 0.61